Source: AIT Therapeutics, Inc.
ET

AIT Granted New Patent for Its Nitric Oxide (NO) Generator and Delivery System

Patent covers technology for a disposable that filters nitrogen dioxide (NO2) gas and programs the system for use

NEW YORK, March 29, 2018 (GLOBE NEWSWIRE) --  AIT Therapeutics, Inc. (OTC:AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced that it has been granted a patent (No. 9,896,337) from the U.S. Patent and Trademark Office (PTO).  The patent, entitled: “Apparatus and Method for Generating Nitric Oxide in Controlled and Accurate Amounts,” covers the filter technology in the Company’s NO Generator and Delivery System that generates nitric oxide from room air.

“The addition of this patent, which covers the disposable portion of our system, is another example of our ability to execute on our plan,” stated Steven Lisi, Chief Executive Officer of AIT. “Our NO generator and deliver system, which weighs about 8lbs, is controlled by the now patented NO2 smart filter, a critical component. Our system can create an endless amount of nitric oxide from ambient air simply by being plugged into any electrical outlet, creating tremendous advantages over the cumbersome high-pressure NO tanks that weigh about 45lbs each and need to be replaced frequently. We look forward to continuing our development for our first indication, persistent pulmonary hypertension of the newborn (PPHN), as well as our clinical development for indications related to acute and chronic lung infections. Additionally, we continue to be on track for filing a 510(k) pre-market notification to the FDA for PPHN around year-end 2018.” 

The claims in the patent involve technology to reduce NO2 from the gas passing through the filter, while leaving the NO concentration substantially unchanged and provide the generator and delivery system with critical information for the accurate delivery of NO gas. Importantly, the patent covers this technology through October 2032.

About Nitric Oxide (NO)
Nitric oxide (NO) is a powerful molecule proven to play a critical role in a broad array of biological functions.  In the airways, NO is believed to play a key role in the innate immune system at concentrations of approximately 200 ppm.  In vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria, both gram-positive and gram-negative, but also against other diverse organisms including mycobacteria, fungi, yeast and parasites, and has the potential to eliminate their multi-drug resistant strains.

About PPHN
Persistent pulmonary hypertension of the newborn (PPHN) is a lethal condition and a secondary to failure of normal circulatory transition at birth.  It is a syndrome characterized by elevated pulmonary vascular resistance (PVR) that causes labile hypoxemia due to decreased pulmonary blood flow and right-to-left shunting of blood.  Its incidence has been reported as 1.9 per 1000 live births (0.4–6.8/1000 live births) with mortality rate ranging between 4–33%.  This syndrome complicates the course of about 10% of infants with respiratory failure and remains a source of considerable morbidity and mortality.  NO gas is a vasodilator and is approved in dozens of countries to improve oxygenation and reduce the need for extracorporeal membrane oxygenation (EMO) in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilator support and other appropriate agents.

About Bronchiolitis
The majority of hospital admissions of infants with bronchiolitis are caused by respiratory syncytial virus (RSV).  RSV is a common and highly transmissible virus that infects the respiratory tract of most children before their second birthday.  While most infants with RSV present with minor respiratory symptoms, a small percentage develop serious lower airway infections, termed bronchiolitis, which can become life-threatening.  The absence of treatment options for bronchiolitis limits the care of these sick infants to largely supportive measures.  AIT’s system is designed to effectively deliver 160 - 400 ppm NO, which has been demonstrated to eliminate bacteria, viruses, fungi and other microbes from the lungs.

About NTM
Nontuberculous mycobacteria (NTM) infection is a rare and serious condition causing debilitating pulmonary disease associated with increased morbidity and mortality.  NTM is an emerging public health concern worldwide because of its multi-drug antibiotic resistance.  Current treatment guidelines suggest a combination of multiple antibiotics delivered continually for as long as two years.  These complex, expensive and invasive regimens have a poor record in the treatment of MABSC.  AIT’s system is designed to effectively deliver 160 - 400 ppm NO, which has been demonstrated to eliminate bacteria, viruses, fungi and other microbes from the lungs and may work against antibiotic resistant bacteria.

About AIT Therapeutics Inc.
AIT Therapeutics Inc. is a clinical-stage medical device and biopharmaceutical company using nitric oxide (NO) to treat respiratory and other diseases. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections that are not effectively addressed with current standards of care, as well as pulmonary hypertension, in various settings. AIT Therapeutics is currently advancing its revolutionary NO Generator and Delivery System in clinical trials for the treatment of bronchiolitis and nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com.

Forward-Looking Statement
This press release contains “forward-looking statements.” Forward-looking statements include statements about our expectations, beliefs, or intentions regarding our product offerings, business, financial condition, results of operations, strategies or prospects. You can identify such forward-looking statements by the words “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” “likely,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks related to: our approach to discover and develop novel drugs, which is unproven and may never lead to marketable products; our ability to fund and the results of further pre-clinical and clinical trials; obtaining, maintaining and protecting intellectual property utilized by our products; our ability to enforce our patents against infringers and to defend our patent portfolio against challenges from third parties; our ability to obtain additional funding to support our business activities; our dependence on third parties for development, manufacture, marketing, sales, and distribution of products; the successful development of our product candidates, all of which are in early stages of development; obtaining regulatory approval for products; competition from others using technology similar to ours and others developing products for similar uses; our dependence on collaborators; and our short operating history. We undertake no obligation to update, and we do not have a policy of updating or revising, these forward-looking statements, except as required by applicable law.

CONTACT
Steven Lisi, Chief Executive Officer
AIT Therapeutics, Inc.
Steve@AIT-Pharm.com

Bob Yedid
LifeSci Advisors, LLC 
Bob@LifeSciAdvisors.com 
(646) 597-6989